{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '13.1', 'RESPONSIBILITIES OF THE INVESTIGATOR(S)', '126', '13.2', 'RESPONSIBILITIES OF THE SPONSOR', '126', '13.3', 'SOURCE DOCUMENT REQUIREMENTS', '126', '13.4', 'USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL', 'REQUEST', '127', '13.5', 'USE OF COMPUTERIZED SYSTEMS', '127', '14', 'ADDITIONAL REQUIREMENTS', '128', '14.1', 'CURRICULUM VITAE', '128', '14.2', 'RECORD RETENTION IN STUDY SITES', '128', '14.3', 'CONFIDENTIALITY', '128', '14.4', 'PROPERTY RIGHTS', '129', '14.5', 'DATA PROTECTION', '129', '14.6', 'INSURANCE COMPENSATION', '129', '14.7', 'SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES', '130', '14.8', 'PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF', 'A SITE', '130', '14.8.1', 'By the Sponsor', '130', '14.8.2', 'By the Investigator', '131', '14.9', 'CLINICAL TRIAL RESULTS', '131', '14.10', 'PUBLICATIONS AND COMMUNICATIONS', '131', '15', 'CLINICAL TRIAL PROTOCOL AMENDMENTS', '132', '16', 'BIBLIOGRAPHIC REFERENCES', '133', '17', 'APPENDICES', '135', 'APPENDIX A LOW, MEDIUM, AND HIGH-DOSE INHALED CORTICOSTEROIDS - CHILDREN', '(6 TO <12 YEARS)', '136', 'APPENDIX B EXAMPLES OF COMMONLY USED ASTHMA CONTROLLER THERAPIES', '137', 'APPENDIX C LIST OF PROHIBITED LIVE ATTENUATED VACCINES', '139', 'APPENDIX D EXAMPLES OF CYP SUBSTRATES WITH NARROW THERAPEUTIC RANGE', '140', 'APPENDIX E ASTHMA SYMPTOM SCORE NUMERICAL RATING SCALE (NRS)', '141', 'Property of the Sanofi Group - strictly confidential', 'Page 31', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'APPENDIX F ASTHMA CONTROL QUESTIONNAIRE-INTERVIEWER ADMINISTERED (ACQ-', 'IA) FOR CHILDREN 6 TO <12 YEARS', '142', 'APPENDIX G PAEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE WITH', 'STANDARDISED ACTIVITIES-INTERVIEWER ADMINISTERED (PAQLQ[S]-IA)', '147', \"APPENDIX H PAEDIATRIC ASTHMA CAREGIVER'S QUALITY OF LIFE QUESTIONNAIRE\", '(PACQLQ)', '153', 'APPENDIX I PAEDIATRIC RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE-', 'INTERVIEWER ADMINISTERED (PRQLQ-IA) - FOR CHILDREN WITH COMORBID', 'ALLERGIC RHINITIS', '156', 'APPENDIX J EURO QOL (EQ-5D-Y) - FOR CHILDREN', '162', 'APPENDIX K GENERAL GUIDANCE FOR THE FOLLOW-UP OF LABORATORY', 'ABNORMALITIES BY SANOFI', '165', 'APPENDIX L DEFINITION OF ANAPHYLAXIS', '170', 'APPENDIX M LIST OF OPPORTUNISTIC INFECTIONS', '171', 'APPENDIX N COUNTRY SPECIFIC REQUIREMENTS', '172', 'APPENDIX O PROTOCOL AMENDMENT HISTORY', '173', 'Property of the Sanofi Group - strictly confidential', 'Page 32', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}